Spatial profiling of METex14-altered NSCLC under tepotinib treatment: Shifting the immunosuppressive landscape

• Published in: Neoplasia (New York, N.Y.) Vol. 57; p. 101063
• Main Authors: Simard, Manon A, Cabrera-Galvez, Carlos, Viteri, Santiago, Geist, Felix, Reischmann, Nadine, Zühlsdorf, Michael, Karachaliou, Niki
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2024; Neoplasia Press; Elsevier
• Subjects: GeoMx; METex14; NSCLC; Original Research; Spatial profiling; Tepotinib; UMAP; Tepotinib; GeoMx; NSCLC; EBUS-TBNA; GO; MHC; ROI; TME; ICI; AUC; CTA; CT; FFPE; H & E; Spatial profiling; PET; METex14
• ISSN: 1476-5586; 1522-8002; 1476-5586
• DOI: 10.1016/j.neo.2024.101063

•Tepotinib downstages NSCLC from IIIB to IA1 in a patient with a METex14 skipping alteration.•GeoMx spatial analysis reveals increased immune cell diversity post-tepotinib.•Tepotinib treatment reduces immunosuppressive genes andincreases tumor cell killing.•Post-tepotinib treatment shifts the tumor microenvironment to a more immune-permissive state. MET inhibitors have demonstrated efficacy in treating patients with non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Advancements in spatial profiling technologies have unveiled the complex dynamics of the tumor microenvironment (TME), a crucial factor in cancer progression and therapeutic response. This study uses spatial profiling to investigate the effects of the MET inhibitor tepotinib on the TME in a case of locally advanced NSCLC with a METex14 skipping alteration. A patient with resectable stage IIIB NSCLC, unresponsive to neoadjuvant platinum-based chemotherapy, received tepotinib following the detection of a METex14 skipping alteration. Paired pre- and post-treatment biopsies were subjected to GeoMx Digital Spatial Profiling using the Cancer Transcriptome Atlas and immune-related protein panels to evaluate shifts in the immune TME. Tepotinib administration allowed for a successful lobectomy and a pathological downstaging to stage IA1. The TME was transformed from an immunosuppressive to a more permissive state, with upregulation of antigen-presenting and pro-inflammatory immune cells. Moreover, a marked decrease in immune checkpoint molecules, including PD-L1, was noted. Spatial profiling identified discrete immune-enriched clusters, indicating the role of tepotinib in modulating immune cell trafficking and function. Tepotinib appears to remodel the immune TME in a patient with METex14 skipping NSCLC, possibly increasing responsiveness to immunotherapy. Our study supports the integration of genetic profiling into the management of early and locally advanced NSCLC to guide personalized, targeted interventions. These findings underscore the need to further evaluate combinations of MET inhibitors and immunotherapies.